Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV prevention strategies after liver transplantation
ACTRN12610000787088Phase 4Completed
- Sponsor
- Austin Health
- Start
- Nov 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of valganciclovir and ganciclovir in cytomegalovirus disease (CMV) (3 arms), sponsored by Austin Health. Primary endpoints: Primary incidence of CMV infection and disease in both arms, Incidence of CMV infection and disease in the high-risk group treated with prophylactic valganciclovir and 1 more. Started Nov 2004; status: completed.
02
Drugs
valganciclovirganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ACTRN12610000787088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000787088.